Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2000-10-10
2003-08-19
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S152000, C514S656000
Reexamination Certificate
active
06608112
ABSTRACT:
BACKGROUND OF THE INVENTION
Pulmonary emphysema, the major component leading to morbidity and mortality in chronic obstructive pulmonary disease (COPD), is the fourth leading cause of death in the United States. Approximately 15 million Americans are affected by COPD with an increasing incidence in women. Smoking is the major risk factor for COPD and accounts for over 90% of cases seen worldwide. Despite this finding, the standard treatment for COPD has changed little over the past 20-30 years.
The etiology of emphysema is multiplex with a variety of different injuries leading to the disease, including structural damage to the lung, defective proteinase inhibitors and diseases which result in overproduction of neutrophils within the lung (Aaron, 1983). Currently the major hypothesis for the pathogenesis of emphysema is the protease-antiprotease theory (Janoff, 1985). This states that an imbalance between the levels of degradative enzymes and their respective inhibitors damages the connective tissue matrix components of the lung.
Emphysema is estimated to affect 1.6 million Americans and has been shown to be directly related to cigarette smoking. Although the primary mechanism leading to lung destruction in this disease is believed to be secondary to an imbalance between proteases and antiproteases, direct evidence of an increase in destructive enzymes within the lung parenchyma has never been demonstrated. The hypothesis was based mainly on the induction of emphysema in animals through intratracheal instillation of nonspecific proteolytic enzymes (Gross et al., 1965). However, the major-focus of many studies has concentrated on elastase as the primary destructive protease due to two particular observations. First, the association between the absence of alpha-1 antitrypsin (an inhibitor of elastase) and emphysema was made through the characterization of the rare hereditary disease, alpha-1 antitrypsin deficiency (Laurell and Erikson, 1963). Secondly, pancreatic and leukocyte elastase produce an emphysema-like phenotype experimentally when instilled intratracheally into certain animal species (Janoff et al., 1977). By contrast, when bacterial collagenase was injected into the lungs of hamsters, no emphysematous lesions developed (Johansen and Pierce, 1972).
The degradation of elastin readily explains the early development of the disease in alpha-1 antitrypsin deficiency (Laurell and Erikson, 1963). However, this represents only 1% of all human patients who suffer from emphysema and the relationship of alpha-1 antitrypsin to the major form of human emphysema which is induced by cigarette smoking remains unclear. In fact, studies over the past 20 years have failed to demonstrate elastase excess or inhibitor deficiency in the development of other forms of human emphysema (for reviews, see Hance and Crystal, 1975). Even in alpha-1 antitrypsin deficiency human patients, there is no direct biochemical evidence for actual proteolysis of elastin in vivo (Hance and Crystal, 1975).
Most importantly perhaps, there are a number of discrepancies between the emphysema observed in the elastase-induced animal model and human emphysema. First, there are differences in the morphological phenotype which have been identified at the ultrastructural level. Secondly, the elastase-induced animals suffer from an acute severe hemorrhagic and inflammatory response which could induce a variety of nonspecific initiators of the emphysematous process (Hoidal et al., 1989). Thirdly, this acute form of emphysema induced after a single intratracheal instillation of enzyme is direct contrast to human emphysema which develops only after chronic insult to the tissue over a period of years. Overall, the lack of direct evidence has led a number of investigators to question the exact role of elastase in human emphysema (Hance and Crystal, 1975; Pickrell and Mauderly, 1981).
A major hypothesis for the pathogenesis of pulmonary emphysema is that alveolar destruction results from an imbalance between proteolytic enzymes and inhibitors in the lung parenchyma. However, direct evidence of an increase in destructive enzymes within the lung parenchyma is lacking.
Chronic obstructive pulmonary disease (COPD), consisting of emphysema and chronic bronchitis, is the fourth leading cause of death in the United States. Approximately 15 million Americans are affected by COPD and there is an increasing incidence in women. Smoking is the major risk factor for COPD and accounts for over 90% of cases seen worldwide. Despite this finding, there are no specific therapies available to limit or prevent these slowly progressive destructive changes (Snider).
Studies over the past 20 years have failed to demonstrate elastase excess or inhibitor deficiency in the development of human emphysema (for reviews, see Hance and Crystal, 1975,). Investigators have identified a variety of protease activity in the bronchoalveolar lavage of smokers. However, cigarette smoking is associated with a 5-10 fold increase in cells recovered by lavage and may not represent what is actually occurring within the lung parenchyma. The chronicity of emphysema and absence of smoking late in the disease make it difficult to implicate these enzymes in the progression of the disease process. This lack of direct evidence has led a number of investigators to question the exact role of elastase in human emphysema (Hance and Crystal, 1975; Pickrell and Mauderly, 1981).
We have previously demonstrated that chronic expression of human collagenase in transgenic mice causes emphysema (D'Armiento et al., 1992). The enzyme used in the animal studies is identical, immunologically and functionally, to the human collagenase of fibroblasts and macrohpages. Most significantly, both of these cell types have been shown to be present within the normal alveolar structure. The development of emphysema upon degradation of collagen in animals implicates this enzyme in the human disease. Despite the lack of evidence demonstrating elastase activity in patients with emphysema and the establishment of emphysema in transgenic mice with the over expression of collagenase (MMP-1), investigators have continued to focus on the role of elastolytic enzymes in the human disease (Shapiro, The pathogenesis of emphysema 30 years later). Most recently, researchers have identified a protease (metalloelastase) secreted by macrophages which is capable of degrading elastin and have hypothesized that this enzyme is responsible for human emphysema. The present study was therefore performed to determine if there was increased expression of collagenase or elastase in the lungs of human patients with emphysema as compared to normal controls.
Matrix metalloproteinase inhibitors are known to block the action of a family of enzymes, the matrix metalloproteinases (Brown, P.
Advan. Enzyme Requl.,
Vol 35, pp 293-300 1995). In the earliest experiments in animal cancer models, matrix metalloproteinase inhibitors were shown to block the spread of cancer and as a result were regarded initially as anti-metastic agents. Further, a series of experiments have shown that, in addition to blocking cancer spread, these inhibitors can also block cancer growth. Experiments have demonstrated this activity for a synthetic matrix metalloproteinase inhibitor, batimastat BB94 (“Batimastat”)
The batimastat-collagenase complex is described in detail and the activities of batimastat analogues are discussed in the light of the protein-inhibitor interactions in Grams, F.
Biochemistry
1995, 34. 14012-14020.
Synthesis of Batimastat (BB94) is described in Campion et al. (1990).
Other known metalloproteinase inhibitors include tetracycline and its derivatives including minocycline, and dilantin.
SUMMARY OF THE INVENTION
The subject invention provides a use of a metalloproteinase inhibitor for the preparation of a pharmaceutical composition for treating human pulmonary emphysema which comprises admixing the metalloproteinase inhibitor in an amount effective to treat human pulmonary emphysema and a pharmaceutically acceptable carrier.
The subj
Chada Kiran
D'Armiento Jeanine
Cooper & Dunham LLP
The Trustees of Columbia University in the City of New York
Travers Russell
White John P.
LandOfFree
Use of metalloproteinase inhibitors in the treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of metalloproteinase inhibitors in the treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of metalloproteinase inhibitors in the treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3120491